Rezolute Shares Plummet Following Clinical Trial Failure
17.12.2025 - 18:53:04Rezolute US76200L3096
The stock of biotechnology firm Rezolute has collapsed in the wake of a disastrous outcome for its most promising drug candidate in a pivotal clinical study. This precipitous decline, which saw shares lose more than 79% of their value within a month, has now triggered legal scrutiny. Two law firms are investigating whether the company may have misled investors. In a contrasting move during the crisis, several of the company’s executives made significant share purchases.
In response to the severe losses sustained by shareholders, law firms Hagens Berman and Faruqi & Faruqi, LLP have now initiated formal investigations. They are examining whether Rezolute may have violated securities laws by making potentially Read more...
